Terazosin Hydrochloride belongs to the class of a1-adrenergic blockers, widely used for the treatment of benign prostatic hyperplasia (BPH) affecting the urogenital tract in men.Certified pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Synonyms: Terazosin hydrochloride dihydrate; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine hydrochloride dihydrate
Molecular Formula: C19H25N5O4 · HCl · 2H2O
Molecular Weight: 459.92
Linear Structural Formula: C19H25N5O4 · HCl · 2H2O
MDL Number: MFCD00941408
Application: These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.
Other Notes: This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.